Proteomics International Laboratories Ltd (PIQ) - Total Liabilities
Based on the latest financial reports, Proteomics International Laboratories Ltd (PIQ) has total liabilities worth AU$4.09 Million AUD (≈ $2.90 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Proteomics International Laboratories Lt to track the company's year-over-year net asset growth rate.
Proteomics International Laboratories Ltd - Total Liabilities Trend (2014–2025)
This chart illustrates how Proteomics International Laboratories Ltd's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Proteomics International Laboratories Lt to measure how efficiently the company converts operating cash flow to free cash.
Proteomics International Laboratories Ltd Competitors by Total Liabilities
The table below lists competitors of Proteomics International Laboratories Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Four Seasons Education Cayman
NYSE:FEDU
|
USA | $228.88 Million |
|
Voyageur Pharmaceuticals Ltd
V:VM
|
Canada | CA$1.85 Million |
|
Rajshree Polypack Limited
NSE:RPPL
|
India | Rs1.62 Billion |
|
Borealis Foods Inc.
NASDAQ:BRLS
|
USA | $69.25 Million |
|
Mexco Energy Corporation
NYSE MKT:MXC
|
USA | $1.30 Million |
|
Great Southern Mining Ltd
AU:GSN
|
Australia | AU$978.40K |
|
M2N Co.Ltd
KQ:033310
|
Korea | ₩46.43 Billion |
|
Cosmos Technology International Berhad
KLSE:0261
|
Malaysia | RM13.10 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Proteomics International Laboratories Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Proteomics International Laboratories Lt worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.61 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Proteomics International Laboratories Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Proteomics International Laboratories Ltd (2014–2025)
The table below shows the annual total liabilities of Proteomics International Laboratories Ltd from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$1.81 Million ≈ $1.28 Million |
+11.58% |
| 2024-06-30 | AU$1.63 Million ≈ $1.15 Million |
-7.20% |
| 2023-06-30 | AU$1.75 Million ≈ $1.24 Million |
-12.49% |
| 2022-06-30 | AU$2.00 Million ≈ $1.42 Million |
+102.21% |
| 2021-06-30 | AU$990.19K ≈ $700.62K |
-11.34% |
| 2020-06-30 | AU$1.12 Million ≈ $790.22K |
+75.99% |
| 2019-06-30 | AU$634.59K ≈ $449.01K |
-22.45% |
| 2018-06-30 | AU$818.30K ≈ $579.00K |
-36.04% |
| 2017-06-30 | AU$1.28 Million ≈ $905.19K |
+53.92% |
| 2016-06-30 | AU$831.17K ≈ $588.11K |
+14.33% |
| 2015-06-30 | AU$727.01K ≈ $514.41K |
+147.54% |
| 2014-06-30 | AU$293.69K ≈ $207.81K |
-- |
About Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for end… Read more